Radyasyona Bağlı Karsinojenez
Özet
Radyasyon maruziyeti, hücreler üzerinde biyolojik hasara yol açarak kanser gelişimini tetikleyen en kritik stokastik (rastlantısal) etkilerden biridir. Bu süreçte radyasyon, DNA üzerinde yapısal hasarlar meydana getirir ve özellikle hücre bölünmesinin aktif olduğu evrelerde tamir mekanizmalarının yetersiz kalmasıyla mutasyonlar kalıcı hale gelerek karsinojenez sürecini başlatır. Stokastik etkilerin deterministik etkilerden farkı, belirli bir eşik dozunun bulunmaması ve maruz kalınan doz miktarı arttıkça kanser oluşma olasılığının doğrusal olarak yükselmesidir. Tarihsel veriler, atom bombası mağdurları, Çernobil kazası ve erken dönem tıbbi uygulamalardan elde edilmiş olup; lösemi, tiroid, meme ve akciğer kanserlerinin radyasyona en duyarlı dokularda geliştiğini göstermektedir. Kanserleşme süreci olan latent dönem, maruziyet yaşına ve doku tipine bağlı olarak değişkenlik gösterir; özellikle proliferasyon hızı yüksek olan çocukluk dönemi maruziyetleri, ilerleyen yaşlarda solid tümör riskini bariz şekilde artırır. Günümüzde modern radyoterapi uygulamaları, hedef dışı sağlıklı dokularda ikincil malignite geliştirme riski taşısa da vazgeçilmez bir tedavi yöntemidir; bu nedenle güncel onkoloji stratejileri, radyasyon kaynaklı bu ikincil tümörlerin erken safhada saptanmasına ve hızla tedavi edilmesine odaklanmıştır.
Radiation exposure is one of the most critical stochastic effects that trigger cancer development by causing biological damage to cells. In this process, radiation induces structural damage to DNA, and especially during active cell division phases, the insufficiency of repair mechanisms causes mutations to become permanent, initiating carcinogenesis. The difference between stochastic and deterministic effects is that stochastic outcomes lack a specific threshold dose, and as the exposure volume increases, the probability of cancer formation rises linearly. Historical data, derived from atomic bomb survivors, the Chernobyl disaster, and early medical interventions, demonstrate that leukemia, thyroid, breast, and lung cancers develop in the most radiosensitive tissues. The latent period of malignancy varies based on exposure age and tissue type; notably, childhood exposures with high proliferation rates significantly increase the risk of solid tumors in later years. Although modern radiotherapy applications carry a risk of inducing secondary malignancies in off-target healthy tissues, they remain an indispensable treatment modality; therefore, current oncology strategies focus strictly on the early detection and rapid management of these radiation-induced secondary tumors.
Referanslar
Wojcik A, Bouffler S, Hauptmann M, et al. Considerations on the use of the terms radiosensitivity and radiosusceptibility. J Radiol Prot. 2018; 38(3):N25-N29.
Goldschmidt H, Sherwin WK. Reactions to ionizing radiation. J Am Acad Dermatol. 1980;3(6):551-79.
Howe GR, McLaughlin J. Breast cancer mortality between 1950 and 1987 after exposure to fractionated moderate-dose-rate ionizing radiation in the Canadian fluoroscopy cohort study and a comparison with breast cancer mortality in the atomic bomb survivors study. Radiat Res. 1996;145(6):694-707
Bostrom PJ, Soloway MS. Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk? Eur Urol. 2007;52(4):973-82.
Holm LE. Cancer occurring after radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys. 1990;19(5):1303-8.
Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;1:56(1):83-8.
Shimizu Y, Kodama K, Nishi N, et al. Radiation exposure and circulatory disease risk: Hiroshima and Nagasaki atomic bomb survivor data, 1950-2003. BMJ. 2010;14;340:b5349.
Leuraud K, Richardson DB, Cardis E, et al. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. Lancet Haematol. 2015; 2(7):e276-81.
Land CE, Bouville A, Apostoaei I, et al. Projected lifetime cancer risks from exposure to regional radioactive fallout in the Marshall Islands. Health Phys. 2010; 99(2):201-15.
Maznik NA. Rol' faktorov neradiatsionnoĭ prirody v formirovanii tsitogeneticheskykh éffektov u évakuantov iz 30-km zony Chernobil'skoĭ AES [Role of non-radiation factors in forming cytogenetic effects in evacuees from a 30-km zone of the Chernobyl Nuclear Power Plant]. Tsitol Genet. 2004;38(6):33-44.
Antunes L, Bento MJ, Sobrinho-Simões M, et al. Cancer incidence after childhood irradiation for tinea capitis in a Portuguese cohort. Br J Radiol. 2020;93(1105): 20180677.
Sun LM, Muo CH, Liang JA et al. Increased risk of cancer for patients with ankylosing spondylitis: a nationwide population-based retrospective cohort study. Scand J Rheumatol. 2014;43(4): 301-6.
Carmichael A, Sami AS, Dixon JM. Breast cancer risk among the survivors of atomic bomb and patients exposed to therapeutic ionising radiation. Eur J Surg Oncol. 2003;Jun 29(5): 475-9.
Berrington de Gonzalez A, Gilbert E, Curtis R et al. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys. 2013;1;86(2):224-33.
Aßenmacher M, Kaiser JC, Zaballa I, et al. Exposure-lag-response associations between lung cancer mortality and radon exposure in German uranium miners. Radiat Environ Biophys. 2019;58(3):321-336.
Hall, E.J., Giaccia, AJ. (2019) Radiobiology For The Radiologist. E.J. Hall, AJ. Giaccia (Eds.) In Radiation Carcinogenesis (8 th ed., pp. 255-299). Philadelphia: Wolters Kluwer.
Özalpan A., (2001) Temel radiobiyoloji. Özalpan Atilla (Ed.) 1. basım, Radyasyonun Geç Etkileri içinde (s. 271-300). İstanbul: Haliç Üniversitesi Yayınları.
Ohno T, Kakinuma S, Kato S, et al. Risk of second cancers after radiotherapy for cervical cancer. Expert Rev Anticancer Ther. 2006;6(1):49-57.
Brenner DJ, Doll R, Goodhead DT, et al. Cancer risks attributable to low doses of ionizing radiation: assessing what we really know. Proc Natl Acad Sci U S A. 2003; 25100(24):13761-6.
Shimizu Y, Kodama K, Nishi N, et al. Ionising radiation and risk of death from leukaemia and lymphoma in radiation-monitored workers (INWORKS): an international cohort study. Lancet Haematol. 2015;2(7):e276-81.
Tubiana M. Contribution of human data to the analysis of human carcinogenesis. C R Acad Sci III. 1999;322(2-3):215-24.
Boice JD Jr. Carcinogenesis--a synopsis of human experience with external exposure in medicine. Health Phys. 1988;55(4):621-30.
Dasu A, Toma-Dasu I. Models for the risk of secondary cancers from radiation therapy. Phys Med. 2017; 42:232-238.
Berrington de Gonzalez A, Gilbert E, Curtis R, et al. Second solid cancers after radiation therapy: a systematic review of the epidemiologic studies of the radiation dose-response relationship. Int J Radiat Oncol Biol Phys. 2013;1;86(2):224-33.
Kourinou KM, Mazonakis M, Lyraraki E, et al. Probability of carcinogenesis due to involved field and involved site radiation therapy techniques for supra- and infradiaphragmatic Hodgkin's disease. Phys Med. 2019 Jan;57:100-106. Munker R, Hiller E, Melnyk A, et al. Second malignancies. Int J Oncol. 1996;9(4):763-76.
